A fundamental belief we hold at Enzychem is that all companies share the ultimate goal of bettering society in one form or another. As a life sciences corporation, we sustain the duty of unremittingly challenging ourselves to work towards a world of fewer illnesses. Thus, we carry an ongoing effort in the research and development of both new and existing drugs, and now as of late, the globalization of EC-18. Through it all, nevertheless, we deem it imperative to establish and invariably follow our code of ethics to ensure proper conduct.
With today’s industrial excellence, all developed nations participate in the mass production of various consumer goods. Yet, we reside in a world of limited resources, where scarcity remains a very real condition.
Enzychem is one of a growing number of businesses that find it compulsory to take environmental responsibility, and incorporate sustainable practices to ensure the preservation of our planet’s resources. With the development of our most recent project, our company has undergone extensive research to find ways to sustainably mass produce EC-18, a scarce substance that is derived from the antlers of deer.
The unfortunate and unequivocal truth is that industrial operations continue to exhaust the earth’s resources. However, there is rising awareness in nations all around the world, making it socially, and in some areas, legally obligatory for businesses to take environmental responsibility.
Entering the global biopharmaceuticals industry is equipped with various obstacles, ranging from the exorbitant costs to complying with the drug administrations of different nations. However, within the recent decade, the Korean biopharma industry put its utmost efforts as well as significant investments into global new drug development, and has been one reason as to why Enzychem’s current project with EC-18 is a reality. In an effort to return the favor, our company is and always will be a supporter for other Korean biopharmaceutical companies in entering the global market.